Zusammenfassung
Das fertige Knochengewebe besteht aus der Knochengrundsubstanz, die vor allem aus Kollagen Typ I besteht, zusätzlich aus unterschiedlichen Eiweißen wie Sialoprotein, Osteopontin, Osteonektin o.a. Eingelagert sind auch Wachstumsfaktoren und Zytokine wie IGF-1, IGF-2 und TGF-β. Stabilisiert wird die biegsame, aber zugkräftige Grundsubstanz durch die Einlagerung des Hydroxylapatits. Griffig ist der technische Vergleich mit Eisenbeton: Das Kollagen entspricht der Eisenarmierung, das Hydroxylapatit dem Zement. Je nach mechanischer Aufgabe werden für die einzelnen Knochen kompakte Strukturen verwendet (z. B. Röhrenknochen), oder es liegt der verzweigte spongiöse, trabekuläre Knochen als Netzwerk von Streben, Stäben und Platten vor (z. B. Wirbelkörper).
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
Literatur
Literatur zu Abschn. 11.1
Cuneo R.C., Judd S., Wallace J.D. et al. (1998) The Australian multicenter trial of growth hormone (GH) treatment in GHdeficient adults. J Clin Endocrin Metab 83: 107–118
Drinkwater B., Nilson K., Chesnut III C. et al.(1984) Bone mineral content of amenorrheic and eumenorrheic athletes. New Engl J Med 311: 277–281
Eriksen E.F., Axelrod D.W., Meisen F. (1994) Bone Histomorphometry. New York: Raven Press, 13–20
Frost H. (1991) A new direction for osteoporosis research: A review and proposal. Bone 12: 429–437
Rao D.S. (1995) Bone and mineral metabolism. Bockus Gastroenterology. 5th edn, Saunders, Philadelphia, pp 464–3471
Uzzan B., Campos I., Cucherat M., Nony P., Boissei J.P., Perret G.Y. (1996) Effects on bone mass oflong term treatment with thyroid hormones: a meta-analysis. J Clin Endocrinol Metab 81, 4278–4289
Ziegler R. (1995) Der Knochen und seine Erkrankungen, Teil I-VI. Dtsch Med Wochenschr 120: 531–532, 571–572, 1091–1092, 1251–1252, 1367–1368, 1445–1446
Ziegler R., Scheidt-Nave C., Scharla S. (1995) Pathophysiology of osteoporosis: unresolved problems and new insights. J Nutr 125: 2033S-2037S
Literatur zu Abschn. 11.2
Adachi J.D. (1997) Corticosteroid-induced osteoporosis. Am J Med Sci 313: 41–49
Black D.M., Cummings S.R., Karpf D.B. et al. (1996) Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Lancet 348: 1535–1541
Chapuy M.C., Arlot M.E., Delmas P.D., Meunier P.J. (1994) Effect of calcium and cholecalciferol treatment for three years on hip fractures in elderly women. BMJ 308: 1081–1082
Civitelli R., Connelli S., Zacchei F. et al. (1988) Bone turnover in postmenopausal osteoporosis. Effect of calcitonin treatment. J Clin Invest 82: 1268–1274
Cummings S.R., Black D.M., Nevitt M.C., et al. (1993) Bone density at various sites for prediction of hip fractures. Lancet 341: 72–75
Dawson-Hughes B., Harris S.S., Krall E.A., Dallal G.E. (1997) Effect of calcium and vitamin D supplementation on bone density in men and women 65 years of age or older. N Engl J Med 337: 670–676
Erdtsieck R.I., Pols H.A.P., Kuijk C.V. et al. (1994) Course of bone mass during and after hormonal replacement therapy with and without addition of nandrolone decanoate. J Bone Miner Res 9: 277–283
Ettinger B., Genant H.K., Cann C.E. (1985) Long-term estrogen replacement therapy prevents bone loss and fractures. Ann Intern Med 102: 319–324
Farley J.R., Tarbaux N.M., Hall S.L. et al.(1988) Evidence that fluoride-stimulated 3[H] thymidine incorporation in embryonic chick calvarial cell cultures is dependent on the presence of a bone cell mitogen, sensitive to changes in the phosphate concentration, and modulated by systemic skeletal effectors. Metabolism 37: 988–995
Farrerons I., Rodriguez de la Serna A., Gua[ntilde]abens N. et al. (1997) Sodium fluoride treatment is a major protector against vertebral and nonvertebral fractures when compared with other common treatments of osteoporosis: a longitudinal, observational study. Calcif Tissue Int 60: 250–254
Felson D.T., Sloutskis D., Anderson J.J. et a1. (1991) Thiazide diuretics and the risk of hip fracture. Results from the Framingham Study. JAMA 265: 370–373
Flicker L., Hopper J.L., Larkins R.G., Lichtenstein M., Buirski G., Wark J.D. (1997) Nandrolone decanoate and intranasal calcitonin as therapy in established osteoporosis. Osteoporosis Int 7: 29–35
Gallacher S.I., Anderson K., Speekenbrink T., Bessent R., Boyle I.T. (1995) A comparison ofthe effects of etidronate, pamidronate, clodronate and calcium on bone density in patients with corticosteroid-dependent lung disease. Calcif Tissue Int 56: 447
Lau E.C.M., Cooper C., Wickham C., Donnan S., Barker D.J.P. (1990) Hip fracture in Hong Kong and Britain. Int J Epidemiol 19: 1119–1121
Leidig G., Minne H.W., Sauer P., Wüster C., Wüster I., Lojen M., Raue F., Ziegler R. (1990) A study of complaints and their relation for vertebral destruction in patients with osteoporosis. Bone and Mineral 8: 217–229
Lutkin E.G., Wahner H.W., O’Fallon W.M. et al. (1992) Treatment of postmenopausal osteoporosis with trans dermal estrogen. Ann Intern Med 117: 1–9
Melton L.J. III, Chrischilles E.A., Cooper C., Lane AW., Riggs B.L. (1992) How many women have osteoporosis? J Bone Miner Res 7: 1005–1010
Obrant K.J., Bngner U., Johnell O., Nilsson B.E., Sernbo I. (1989) Increasing age-adjusted risk of fragility fractures: a sign of increasing osteoporosis in successive generations? Calcif Tissue Int 44: 157–167
Overgaard K., Hansen M.A., Birk Jensen S., Christiansen C. (1992) Effect of salcatonin given intranasallyon bone mass and fracture rate in established osteoporosis: a dose-response study. BMJ 305: 556–561
Quigley M.E.T., Martin P.L., Burnier A.M., Brooks P. (1987) Estrogen therapy arrests bone loss in elderly women. Am J Obstet Gynecol 156: 1516–1523
Ravn P., Clemmesen B., Riis B.J., Christiansen C. (1996) The effect on bone mass and bone markers of different doses of ibandronate: A new bisphosphonate for prevention and treatment of postmenopausal osteoporosis: A 1-year, randomized, double-blind, placebo-controlled dose-finding study. Bone 19: 527–533
Riggs B.L., Melton L.J. III (1986) Involutional osteoporosis. N Engl J Med 314: 1676–1686
Riggs B.L., O’Fallon W.M., Lane A., Hodgson S.F. et al. (1994) Clinical trial of fluoride therapy in postmenopausal osteoporotic women: extended observations and additional analysis. J Bone Miner Res 9: 265–275
Scheidt-Nave C., Felsenberg D., Kragl G., Brucker T., LeidigBruckner G., Wüster C., Ziegler R. (1998) Vertebrale Deformität als Index der osteoporotischen Wirbelfraktur-eine externe Konstruktvalidierung anhand von Knochendichtemessdaten. Medizinische Klinik 93(Suppl. II):46–55
Seilers T.A., Mink P.I., Cerhan J.R. et al. (1997) The role of hormone replacememnt therapy in the risk for breast cancer and total mortality in women with a family history of breast cancer. Ann Intern Med 127: 973–980
Storm T., Kollerup G., Thamsborg G., Genant H.K., Sorensen O.H. (1996) Five years of clinical experience with intermittent cyclical etidronate for postmenopausal osteoporosis. J Rheumatol 23: 1560–1564
Thiebaud D., Burckhardt P., Melchior J. et al. (1994) Two years’s effectiveness of intravenous pamidronate (APD) versus oral fluoride for osteoporosis occurring in the postmenopause. Osteoporosis Int 4: 76–83
Tilyard M.W., Spears G.F.S., Thomson J., Dovey S. (1991) Treatment of postmenopausal osteoporosis with calcitriol or calcium. J Engl J Med 326: 357–362
Ziegler R. (1995) Der Knochen und seine Erkrankungen, Teil I-VI. Dtschmed Wschr 120: 531–532, 571–572, 1091–1092, 1251–1252, 1367–1368, 1445–1446
Literatur zu Abschn. 11.3
Glorieux F.H. (1996) Hypophosphatemic vitamin D-resistant rickets. In: Favus M.J. (ed) Primer on the metabolic bone diseases and dis orders of mineral metabolism. 3rd edn, Lippincott & Raven, Philadelphia, pp 316–319
Kruse K. (1990) Metabolische Osteopathien im Kindesalter. Internist 31: 745–755
Offermann G., Manhold C. (1978) Osteomalazie bei türkischen Gastarbeitern in Deutschland. Inn Med 5: 103–108
Sparagana M. (1987) Tumor-induced osteomalacia: long-term follow-up of two patients cured by removal of their tumors. J Surg Oncol 36: 198–205
Literatur zu Abschn. 11.4
Cartwright E.I., Gordon M.T., Freemont A.I., Anderson D.C., Sharpe P.T. (1993) Paramyxovirus and Paget’s disease. J Med Virol 40: 133–141
Grauer A., Klar B., Scharia S., Ziegler R. (1994) Long-term efficacy of intravenous pamidronate in Paget’s disease of bone. Seminars in Arthritis and Rheumatism 23: 283–284 Paget J (1877) On a form of chronic inflammation ofbone (osteitis deformans). Med Chir Trans 60: 37
Rebel A., Bregeon C., Basle M., Kalkani K., Patezour A., Filmon R. (1975) Osteoclastic inclusions in Paget’s disease of bone. Rev Rhum Mal Osteoartic 42: 637–641
Roux C., Gennari C., Farrerons J. et al. (1995) Comparative prospective double-blind, multicenter study of the efficacy of tiludronate and etidronate in the treatment of Paget’s disease of bone. Arthritis Rheum 38: 851–858
Schmorl G. (1932) Über Ostitis deformans Paget. Virch Arch Path Anat 283: 694
Ziegler R. (1990) M. Paget des Skeletts. Internist 31: 763–768
Ziegler R., Holz G., Rotzier B., Minne H. (1985) Paget’s disease of bone in West Germany: Prevalence and distribution. Clin Orthop 194: 199–204
Literatur zu Abschn. 11.5
Albers-Schönberg H. (1904) Röntgenbilder einer seltenen Knochenerkrankung. Münch Med Wochenschr 51: 365
Coccia P.F., Krivit W., Cervenka J. et al. (1980) Successful bonemarrow transplantation for infantile malignant osteopetrosis. N Engl J Med 302: 701–708
Helfrich M.H., Aronson D.C., Everts V., Mieremet R.H.P., Gerritsen E.J.A., Eckhardt P.G., Groot C.G., Scherft J.P. (1991) Morphologic features of bone in human osteopetrosis. Bone 12: 411–419
Kahler S.G., Bums J.A., Aylsworth A.S. (1984) A mild autosomal recessive form of osteopetrosis. Am J Med Genet 17: 451–464
Key L.L., Ries W.L., Schiff R. (1987) Osteopetrosis associated with interleukin-2 deficiency. J Bone Miner Res 2(Suppl. 2):85
Loria-Cortes R., Quesada-Calvo E., Cordero-Chaverri E. (1977) Osteopetrosis in children. A report of 26 cases. J Pediatr 91: 43–47
Teitelbaum S.L., Tonadravi M.M., Ross F.P. (1996) Osteoclast biology. In: Marms R., Feldman D., Kelsey J. (eds) Osteoporosis, Academic Press, San Diego, pp 61–94
Literatur zu Abschn. 11.6
Devogelaer J.P., Malghem I., Maldague B., Nagant de Deuxchaisnes C. (1987) Radiological manifestations of bisphosphonate treatment with ADP in a child suffering from osteogenesis imperfecta. Skeletal Radiol 16: 360–363
Henethorn P.S., Raducha M., Fedde K.N., Lafferty M.A., Whyte M.P. (1992) Different missen se mutations at the tissues-nonspecific alkaline phosphatase gene locus in autosomal recessively inherited forms of mild and severe hypophosphatasia. Proc Natl Acad Sci USA 89: 9924–9928
Liens D., Delmas P.D., Meunier P.J. (1994) Long-term effects of intravenous pamidronate in fibrous dysplasia of bone. Lancet 323: 953–954
Pfeilschifter I., Ziegler R. (1998) Wirkung von Pamidronat auf das Beschwerdebild und den Knochenstoffwechsel bei Patienten mit fibröser Dysplasie und McCune-Albright-Syndrom. Medizinische Klinik 99: 352–359
Shenker A., Weinstein L.S., Sweet D.E., Spiegel A.M. (1994) An activating Gs a mutations is present in fibrous dysplasia of bone in the McCune-Albright syndrome. J Endocrin Metab 79: 750–755
Stöß H., Pesch H-J., Spranger J. (1979) Therapie der Osteogenesis imperfecta mit (+)-Catechin. Dtsch Med Wochenschr 50: 1774–1778
Whyte M.P. (1996) Osteogenesis imperfecta. In: Favus M.J. (ed) Primer on the Metabolic bone diseases and dis orders of mineral metabolism. Lippincott & Raven, Philadelphia, pp 382–385
Whyte M.P. (1996) Hypophosphatasia. In Favus M.J. (ed) Primer on the metabolic bone diseases and disorders of mineral metabolism. Lippincott & Raven, Philadelphia, pp 326–328
Ziegler R., Raue F., Cotta H. et al. (1987) Osteogenesis imperfecta und juvenile Osteoporose. Behandlungsversuche mit synthetischem Humancalcitonin. Therapiewoche 37: 1895–1904
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2001 Springer-Verlag Berlin Heidelberg
About this chapter
Cite this chapter
Ziegler, R. (2001). Osteoporose und metabolische Knochenerkrankungen. In: Nawroth, P.P., Ziegler, R. (eds) Klinische Endokrinologie und Stoffwechsel. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-56784-1_11
Download citation
DOI: https://doi.org/10.1007/978-3-642-56784-1_11
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-642-62970-9
Online ISBN: 978-3-642-56784-1
eBook Packages: Springer Book Archive